Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

PHASE4RecruitingINTERVENTIONAL
Enrollment

939

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Heart Failure
Interventions
DRUG

Acetazolamide

1\. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.

DRUG

Metolazone 2.5 MG

2\. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.

OTHER

Double-placebo

This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).

Trial Locations (3)

2400

NOT_YET_RECRUITING

Bispebjerg Hospital, Copenhagen

2650

RECRUITING

Amager-Hvidovre Hospital, Hvidovre

2730

RECRUITING

Herlev-Gentofte hospital, Copenhagen

All Listed Sponsors
lead

Johannes Grand

OTHER

NCT06166654 - Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload | Biotech Hunter | Biotech Hunter